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Because activated B cells express Fas
and can die in a Bim-dependent manner,
it is tempting to suggest that both Bim
and Fas play crucial roles in regulating B
cell numbers via cell autonomous pro-
cesses. B cell-specific deletion of Fas
led to accumlation of lymphocytes (to
the same extent as seen in T cell- plus B
cell-specific deletion—although in the B
cell-specific case, without expansion of
the B220+CD3+ T cells), suggesting that
Fas-mediated B cell death plays a role in
the regulation of B cell numbers. The rela-
tive contribution of T cells or B cells lack-
ing Fas signaling to disease is difficult to
assess for the reasons mentioned above,
however, because the defective T cells
show enhanced expression of FasL.
To fully understand the complex inter-
play between these modes of cell death
in the control of lymphocyte numbers,
what we need, it seems, is a way to spe-
cifically block Fas signaling in a specific
cell type while eliminating the effects of
Bim in the same or different cell. But there
is a problem; Fas signals via an adaptor
molecule, FADD, and an initiator caspase,
caspase-8, and elimination of either of
these impacts the ability of the T cell to
activate and/or proliferate (reviewed in
Pellegrini et al., 2005). How this occurs,
and whether we can interfere with the
death pathway while sustaining the acti-
vation pathway mediated by these mole-
cules, is not yet known (but there are hints
that the answer is yes, we can). But per-
haps the important message is that this
pathway plays two roles, positive and
negative, in the control of lymphocyte
number. A T cell that loses Fas upregu-
lates FasL to kill other cells (and dies as
survival factors become limiting). If in-
stead it loses Fas signaling (FADD, or cas-
pase-8) it does not effectively expand.
Loss of Bim allows the cell to survive
under limiting conditions, but these cells
are nevertheless killed by Fas signaling
(or are at least limited by a Fas-dependent
process, such as killing of dendritic
cells).
One autoreactive T lymphocyte, with
unchecked capability for expansion, can
kill the organism. That’s why the game of
T cell survival is so hard to win.
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How critical is it for T cells to stably arrest on antigen-presenting cells? In this issue of Immunity, Scholer et al.
(2008) demonstrate profound effector and memory defects for CD8+ T cells encountering ‘‘nonsticky’’
antigen-presenting cells lacking intercellular adhesion molecule-1.It has become apparent that the stable
interaction of T cells with antigen-present-
ing cells (APCs) is not simply dictated by
the presence of peptide-MHC (pMHC)
complexes on the stimulating APCs.
In vivo, T cells often circle for many hours,
loosely engaging in transient interactions
with APCs before arresting to form stablecontacts (Mempel et al., 2004;Miller et al.,
2004). But what changes occur that per-
mit this stable interaction?
Scholer et al. and others started to
address this with the observation that
dendritic cells (DCs) from immunized ani-
mals exhibit a modest upregulation of in-
tercellular adhesion molecule-1 (ICAM-1)Immunitythat peaks synchronously with the period
of time when T cells stably arrest on the
DCs in vivo. In vitro, they subsequently
demonstrated the expected result that
ICAM-1-deficient DCs are defective in
mediating prolonged T cell engagements.
Such a result is, in effect, a modern ver-
sion of lymphocyte-function-associated28, February 2008 ª2008 Elsevier Inc. 143
Immunity
PreviewsFigure 1. Requirements for ICAM-1 on APCs Mapped Directly or Indirectly to T Cell-APC
Interactions
The top shows the cell-intrinsic requirement for ICAM-1. ICAM-1 is upregulated on APCs after short inter-
actions with T cells, thereby leading to enhanced adhesion and a stable synapse. The stable synapse im-
proves activation and amplifies TCR signals and polarity. The bottom shows the scaffolding requirement
for ICAM-1. Dynamic T cell interactions cause upregulation of ICAM-1 on APCs in addition to increasing
expression of other costimulatory molecules. These factors increase adhesion of both the original T cell
and other bystander cells. The aggregation of these cells leads to amplification of cytokine and chemokine
signaling. The APC then matures into a scaffold-competent cell, able to form stable synapses with anti-
gen-specific T cells. Signaling and polarization are amplified, and T cell clusters increase local concentra-
tions of cytokines. In both cases, ICAM-1 expression is necessary for stable T cell-APC synapses that
enhance CD69 expression, proliferation, IFN-g secretion, and memory cell formation.antigen-1 (LFA-1) blockade experiments
performed with some of the first mono-
clonal antibodies in mixed-leukocyte re-
actions (MLRs); such assays showed
LFA-1-ICAM interactions were critical for
T cell activation. In another modern turn,
they subsequently show a profound re-
duction in cell arrest on APCs in vivo as
well.
But what is the mechanism of the
ICAM-1 contribution and how does this
relate to cell arrest? Previously, it has
been argued that ICAM-1 ‘‘costimulates’’
T cell activation through LFA-1 signaling
in much the same way that B7 costimu-
lates T cells through CD28. However, as
shown here again, LFA-1-ICAM engage-
ment appears to function quite distinctly
from CD28 costimulation. Notably, the
absence of ICAM-1 from the entire host
had limited effects on early measures
of TCR signaling such as CD69 upregula-
tion or upon proliferation over the first
3 days.144 Immunity 28, February 2008 ª2008 ElseIncontrast,activationofTcells in vivoun-
der conditions in which ICAM-1 is lacking
resulted in shorter T-APC contact times.
Shorter contact correlated with specific
defects in CD8+ T cell priming for gamma-
interferon (gIFN) production as well as
substantial defects in memory formation.
Furthermore, cells stimulated under such
conditions exhibit a proliferative profile re-
sembling ones generated by other ‘‘toler-
izing’’ stimuli such as direct targeting of
antigen to DEC-205+ DCs in the absence
ofCD40 engagement. Although cells stim-
ulated in the absence of ICAM-1 resemble
such tolerance, it is not yet proven that
they are identically ‘‘tolerant.’’ It should
also be noted that the majority of toler-
ance-related results in this study also
derive from experiments in which ICAM-1
was lacking in the entire host and not just
on the APC. The possible effect of ICAM-1
on other aspects besides T cell-APC con-
tacts (for example, in effective homing
and trafficking) should not be discounted.vier Inc.The implications here are that pro-
longed APC interactions strengthen the
T cell response, in part by regulating the
ability of T cells to stably assemble. An-
other possibility is that short interactions
are inherently tolerogenic and inhibitory
for memory or effector cell formation.
A single long-lived interaction might over-
come this. Whereas this promotes the
concept that a stable interaction in vivo
generates a full activation program, the
complete components of such a program
remain a mystery.
What is the nature of the ‘‘complete’’
activation program that is set into play
when LFA-1-ICAM interactions are per-
mitted to occur? In the simplest scenario
(Figure 1), longer contacts are likely to
allow greater recruitment of TCRs and as-
sociated signaling molecules to the site of
pMHC engagement, the immunological
synapse (IS). A higher density of receptors
correlates with a higher signal output
(Grakoui et al., 1999), and so a simplistic
model would argue that longer duration
times and associated accumulations at
the IS would provide improved activation
via a T cell intrinsic effect. An extension
of this idea was recently provided by
Chang et al., who proposed that more
stable interactions are better at inducing
a stable cell polarization program within
T cells and thus in promoting differentia-
tion through a process of asymmetric
cell division (Chang et al., 2007). This is
also a cell-intrinsic mechanism in which
longer and more stable interactions
may facilitate a greater degree of commit-
ment to a hyperpolarized polarity state
within the T cell. The in vitro data of
Scholer et al. (2008) support this sort of re-
stricted requirement for ICAM-1 inmediat-
ing the arrest phase because in vitro-
matured bone-marrow-derived dendritic
cells lacking ICAM-1 were specifically
defective in stopping. Nonetheless, the
situation in vivo may prove more compli-
cated.
Sticky APCs may also serve as a com-
munal meeting ground for multiple T cell
interactions over time. In such a model
(Figure 1), the ICAM-1 is also a broad pre-
requisite for a DC to act as a scaffold for
a great many different cell types. Loss of
ICAM-1 would then represent a defect in
amplification capability; each T cell
interaction is unable to improve the stimu-
latory quality of the APC in multiple re-
spects, including expression of other
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Previewscostimulatory molecules such as B7 and
CD40, not just with respect to its ICAM-
1 expression.
Notably, over time andmultiple encoun-
ters, a qualified APC might effectively
become a repository for a collective his-
tory of multiple T cell responses. One
way of storing this information is probably
in the form of bound inflammatory chemo-
kines. DCs can be shown to effectively
present the T zone chemokine SLC on
their surface, thereby altering synapse
dynamics (Friedman et al., 2006). Two
studies from the past two years support
the existence of a CCR5-ligand ‘‘tagging’’
method whereby T cells that are weakly
activated can be recruited to dendritic
cells that are or were actively engaging
other T cells (Castellino et al., 2006;
Hugues et al., 2007). This mechanism ap-
pears to take advantage of chemokines
made during early rounds of T-DC interac-
tions, to recruit T cells to sites where other
T cells have begun to assemble. Because
chemokine-mediated recruitment typi-
cally uses LFA-1-ICAM-1 interactions in
lymphocytes, this would be a program
that may also be cut short by loss of
ICAM-1 on DCs.
In either case, these results bear a
curious relationship to recent studies of
protein kinase Cq (PKCq)-deficient T cells,
which have the dual phenotype of poor IS
stability and, at least in some circum-
stances, increased IL-2 production (Sims
et al., 2007). In that study, it was argued
that continued scanning, an effect nor-
mally promoted by PKCq, provided a pos-
itive benefit to T cells because they effec-
tively could accumulate activating signalsfrom many APCs. Subsequently, they
may preferentially arrest on the ‘‘best.’’
Such a result is not in conflict with the
Scholer result. Indeed, transient-engage-
ments may allow T cells to collectively
select the best APCs in the lymph node
and ultimately give them the best chance
of collectively aggregating on ICAM-1-
positive (or upregulated) DCs when
enough short engagements have been
made with that APC. It is then informative
that PKCq deletion, although being some-
what of a positive benefit for T cell IL-2
production in an antigen-rich environment
(e.g., on bilayers where each move away
from one IS means that the cell can get
more signal), is rather detrimental for acti-
vation and effector development of T cells
in vivo (Marsland et al., 2004), in which
being unable to stop means being unable
to commit when the best APC is finally
found.
It is interesting to further speculate
on the possibilities for adhesion to play
a more generalized role in regulating
systemic functions in immunity. A sticky
surface could come to contain multiple
activating T cells—indeed, such large
clusters have been observed in vivo. This
physical proximity would serve to in-
crease local concentrations and availabil-
ity of cytokineswithin the scaffold. In addi-
tion, it may provide amechanismbywhich
a collection of initially weak TCR signals
may, through bulk action, evade the spoil-
ing effects of regulatory T cells that might
also compete for APC occupancy (Tang
et al., 2006). In the coming years, it will
be interesting then to differentiate purely
T cell intrinsic effects of stopping for aImmunitsynapse as compared to the role that
stopping has in promoting larger system-
wide properties in which T cells and DCs
participate.
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